Deguelin was identified as a functional inhibitor of FBXO22 by utilizing the CMap database and was shown to increase lung cancer radiosensitivity in vitro and in vivo with a favorable safety profile, exhibiting substantial clinical translation prospects. The gene discussed is FBXO22; the disease is lung cancer.